Iovance Taps Former Arvinas CMO to Drive TIL Therapy Expansion…

Event summary

Iovance Biotherapeutics appointed Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer effective September 30, 2026.
Berkowitz previously led clinical strategy at Arvinas, securing FDA approval for a targeted protein degradation therapy.
He also oversaw regulatory approvals for CAR-T therapies Abecma and Breyanzi at Bristol Myers Squibb.
Iovance granted Berkowitz inducement stock options and restricted stock units covering 450,000 shares.
Berkowitz's compensation includes performance-based vesting tied to regulatory milestones.

The big picture

Iovance's appointment of Berkowitz underscores its push to expand the reach of TIL therapies beyond advanced melanoma. Berkowitz's experience in securing regulatory approvals for innovative cell therapies positions Iovance to compete more aggressively in the solid tumor space. The move comes as the biotech industry increasingly focuses on next-generation immuno-oncology approaches, with TIL therapies emerging as a key frontier.

What we're watching

Regulatory Milestones: Whether Berkowitz can accelerate Iovance's TIL therapy approvals across new solid tumor indications.
Market Expansion: The pace at which Iovance can scale its TIL platform to earlier treatment settings and additional markets.
Execution Risk: How Berkowitz's track record in global drug development will translate to Iovance's next-generation TIL programs.